|

Allied healthcare products Inc, ($AHPI) leaning bullish

The Corona Virus has provided some tremendous rallies in the healthcare and bio science sectors. Allied Healthcare Products Inc. is one of those names that has gone parabolic with the COVID-19 spreading worldwide. It still remains very technical, and I think there could be one more leg up before the rally is complete. Lets take a look at what they do as a company:

“Allied Healthcare Products, Inc. is a leading manufacturer of medical gas construction equipment, respiratory therapy equipment, home healthcare products, and emergency medical supplies. Our products appear worldwide in a range of medical applications, including hospital care, sub-acute treatment, long-term care, home healthcare, and medical emergencies.”

The 2020 rally, in particular, has more to do with their ventilator sales more than anything. The USA is in dire need of ventilators so speculators have flocked to this company. So with that said, the Elliott Wave view seems to be counting technically clean. Let’s take a look below at the 4H view.

Allied Healthcare Products Inc. Elliott Wave 4H View

AHPI

So I’ll be taking a look at this 4H chart in log.  Because this stock has had such a breathtaking rally, a linear chart does not represent the chart as I believe it should be viewed.  From the all time lows, wave ((1)) is set at $5.00 and ((2)) at $2.00.  From there wave ((3)) is set at 45.00 and wave ((4)) is playing out as a contracting triangle.  Blue (E) of ((4)) is expected a bit lower near the 16.30 area where it meets the trendline.  After Blue (E) is set, an opportunity for a ((5)) thrust is expected for a Red I top.  However, If $12.50 is broken, this count will be invalid and will be favored the top has been set at $45.

Author

Elliott Wave Forecast Team

Elliott Wave Forecast Team

ElliottWave-Forecast.com

More from Elliott Wave Forecast Team
Share:

Editor's Picks

EUR/USD tests 1.1800 barrier above 50-day EMA

EUR/USD gains ground after three days of losses, trading around 1.1790 during the Asian hours on Thursday. The 14-day Relative Strength Index momentum indicator at 47 (neutral) reflects easing momentum. The RSI below 50 keeps momentum balanced and could limit follow-through.

GBP/USD struggles near four-week low vs. USD, below 1.3500 amid BoE rate cut bets

The GBP/USD pair is seen consolidating its weekly losses registered over the past three days and oscillating in a narrow range near a four-week trough, touched during the Asians session on Thursday. Spot prices currently trade just below the 1.3500 psychological mark and seem vulnerable to slide further.

Gold consolidates below $5,000 amid geopolitical risk, hawkish FOMC Minutes

Gold extends its sideways consolidative price move through the Asian session on Thursday and remains below the $5,000 psychological mark as traders seem hesitant amid mixed cues. The US Dollar preserves its strong gains to over a one-week high in the wake of somewhat hawkish Minutes of the US Federal Reserve’s January monetary policy meeting. 

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments. The technical outlook suggests further gains if INJ breaks above key resistance.

Mixed UK inflation data no gamechanger for the Bank of England

Food inflation plunged in January, but service sector price pressure is proving stickier. We continue to expect Bank of England rate cuts in March and June. The latest UK inflation read is a mixed bag for the Bank of England, but we doubt it drastically changes the odds of a March rate cut.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.